OncoMatch/Clinical Trials/NCT03991832
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
Is NCT03991832 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Olaparib and Durvalumab for glioma.
Treatment: Olaparib · Durvalumab — This is a phase 2 study of the combination of drugs olaparib and durvalumab for the treatment of isocitrate dehydrogenase or (IDH) mutated solid tumors. The purpose of this study is to assess the efficacy of the drug combination via overall response rate and overall disease control rate. It is believed that giving olaparib and durvalumab together would be more useful when given to patients with IDH-mutated solid tumors than giving each drug alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Cholangiocarcinoma
Tumor Agnostic
Biomarker criteria
Required: IDH1 any mutation
IDH mutant
Required: IDH2 any mutation
IDH mutant
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: PARP inhibitor (olaparib)
Any previous treatment with PARP inhibitor or PD-1/PD-L1 inhibitors including olaparib and durvalumab
Cannot have received: anti-PD-1 therapy (durvalumab)
Any previous treatment with PARP inhibitor or PD-1/PD-L1 inhibitors including olaparib and durvalumab
Cannot have received: anti-PD-L1 therapy (durvalumab)
Any previous treatment with PARP inhibitor or PD-1/PD-L1 inhibitors including olaparib and durvalumab
Lab requirements
Blood counts
normal organ and bone marrow function measured within 28 days prior to administration of study treatment
Kidney function
normal organ and bone marrow function measured within 28 days prior to administration of study treatment
Liver function
normal organ and bone marrow function measured within 28 days prior to administration of study treatment
Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify